chrisvoncsefalvay/vaers-outcomes huggingface dataset:
- 4/17/21, ~4:30 pm: 1st dose of Pfizer COVID?19 vaccine - 4/17/21, ~7:30 pm: Tingling in face, more concentrated on left side of face. - 4/17/21, ~8:30 pm: ER visit upon recommendation of a nurse phone line. During the ER visit, the tingling turned into numbness (novocaine like feeling). There was also tingling in front left of tongue. Benadryl was given  (tongue tingling seemed to go away with Benadryl but nothing else) and sent home ~11:30 pm. The ER doctor advised coming back if symptoms got worse.
Within four hours I was profusely sweating, had a fever, with severe body aches. I was bedridden and severely nauseous. I thought my symptoms would subside within a day or two. They continued for a solid week. Why doesn't anyone tell you this? When I was vaccinated with Typhoid, at least they gave me full disclosure of what to expect. I have improved enough to fill out this report; yet, I am still highly nauseous after a week and still fighting other symptoms.
Info has been rec'd concerning  a pt who was vaccinated with hepatitis B vaccine recombinant. Subsequently, 2 days after administration of their 1st dose of the hepatitis B vaccine recombinant, the pt experienced nausea and developed loose stools, the outcome of the pt's nausea and loose stools was unknown.  Additional information has been requested.
Pt called shortly after receiving shot complaining of pain up and down her arm. Says she has never experienced this with a flu shot before. Pain was not localized. Followed up with pt later in the evening. She says her arm was much better, but had localized pain at injection site.
COVID-19; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On MAY-2022, the patient experienced covid-19. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of covid-19 was not reported. This report was non-serious. This report was associated with a product quality complaint 90000241763.
Patient in her bedroom sitting on floor, everything went black, felt "dizzy". Stood up, called out to Mom, lost consciousness. Mom ran in, pt leaning against closet doors, very pale; face contorted, then arms, drooled, arms shaking. Mom held her. Patient moved her arms to support her head, apparently to get more comfortable. Then arms down to sides and head turned to side; head rhythmically hit floor few times. Shaking lasted 1.5 to 2 minutes. Eyes open, breathing but still unresponsive 5 minutes or less gradually came back. Slow to answer to mom, not confused no weakness. EMS arrived. Woke up felt dizzy, nauseated, vision black blur. To ER.
This spontaneous report has been received from a healthcare worker concerning a patient of unknown age and gender. The patient's concomitant medication, pertinent medical history and drug reactions/allergies were not reported. On 15-JAN-2016 the patient was administered a dose of improperly stored ROTATEQ (strength, dose not reported, lot # L013202 and Exp. date 27-JAN-2017) orally. The vaccine was exposed to 34 F for 8 hours, and there was no previous temperature excursion. No adverse effect was reported. This is one of several reports received from the same reporter. Additional information has been requested.
Patient suffered a cluster of 10 seizures in the time period between 4:45 PM and 8:30 PM. The seizures began at home and terminated after admission to the hospital.  None of the medical personnel who treated patient including her pediatician considered the seizures had any connection to the Hepatitis A vaccination administered the preceding day.
Chills. Rash spreading through my arms, under arms and left side of abdomen. Itching (severe). Rash has lasted over 3 weeks now. TX: Antibiotic (10 days), BENADRYL/steroid (oral), topical steroid cream.
FEVER; NAUSEA; BODY ACHES; CHILLS; MALAISE; This spontaneous report received from a patient concerned an adult male. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 30-MAR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On MAR-2021, the subject experienced body aches. On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced malaise. On MAR-2021, the subject experienced nausea. On 31-MAR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 101 approximately. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever, chills, body aches, malaise and nausea was not reported. This report was non-serious.
Beginning about 3 hours after the injection, I had a headache and a fever. Without fever reducing medication, my fever reached 102.9 degrees. 24 hours after the injection, I still have a fever of about 100 degrees. Also, there is some pain around my injection site and some body aches.
Headache Narrative:  Headache, myalgia, fatigue, injection site pain 08/27/2021 08/30/2021. In addition night sweats with chills. Resulted in 2 days missed from work.
Aches, tired, diarrhea. Started a few days after shot and is still ongoing and seems to be getting worse.
Pain in right shoulder after injection with a diagnosis of Right Subacrominl bursitis secondary to  hep B injection.
A physician reported the occurrence of numbness in the arms and legs of a female of unspecified age who was vaccinated with hepatitis B vaccine recombinant (Engerix-B) for prophylaxis. The pt's medical history and concurrent conditions were not specified. Concurrent medications included methadone hydrochloride. On an unspecified date, the pt received her 1st injection of Engerix-B. One week post-immunization, the pt began to experience "numbness in arms and legs at rest." As of 03/05/2003, the physician reported that the numbness had improved.
Information has been received from a physician via medical records concerning a 20 weeks male patient who on 24-SEP-1992 was vaccinated with the first dose of RECOMBIVAX HB (lot number 603895/0748V) in the right leg. In the same day the patient received the second dose of HIBTITER (Lot number M125JD), ORIMUNE (Lot number 32093106590) and ACEL-IMUNE (Lot number 318908). On 17-NOV-1992, the patient received the second dose of RECOMBIVAX HB (Lot number 603895/0748V) in the left leg. On the same day the patient received the third dose of HIBTITER (Lot number M020JE) and ACEL-IMUNE (Lot number 318908). On 11-AUG-1993, the patient received the fourth dose of HIBTITER (Lot number M170KB). On 10-NOV-1993 the patient received the fourth dose of ACEL-IMUNE. On 09-JUN-1994, the patient received the third dose of RECOMBIVAX HB (Lot number) in the right arm. On 14-MAY-1997, the patient received the fourth dose of ORIMUNE and the fifth dose of DTaP. The patient's vaccination history also included: 07-MAY-1992 the patient received the first dose of HIBTITER (Lot number M600JD), the first dose of ORIMUNE (Lot number 31493706464) and the first dose of ACEL-IMUNE (Lot number 318908). The patient also received MMR II on 05-AUG-1997 and on 09-NOV-2001. VARIVAX (Merck) on 24-JAN-1996 and on 02-OCT-2007. MENACTRA on 02-OCT-2007. On 22-JUN-2010 the patient's serum hepatitis B surface antibody screen showed a value of 0.71, it was reported that he was no longer immune per blood test titers. At the time of the report the patient's present status was unknown. This is an amended report. The adverse event of overdose was deleted since the dose administered was not specified. In addition, an adverse event of inappropriate schedule of vaccine administered was added to reflect that the second dose of RECOMBIVAX HB was administered later than one month of receiving the first dose. Additional information is not expected.
intractable episodic headaches, malaise and fatigue. Timing of symptoms correlates with her 2nd dose of covid vaccine. Being treated by her primary care provider as hyperimmune response from vaccine.
Dizziness and headache started about 1-2 hours after shot. Felt like I was going to fall when I stood up. Last about 12 hours. Very sore arm at the injection site.
Information has been received from a physician concerning a 20 year old female who was vaccinated with a dose of Gardasil.  Within seconds, the patient turned blue and passed out and was out for about one to one and a half minutes.  Unspecified medical attention was sought.  At the time of this report, the patient's outcome was unknown.  No product quality complaint was involved.  Additional information has been requested. This is in follow-up to report (s) previously submitted on 2/14/2008. Information has been received from a physician concerning a 23 year old female with epilepsy who on 28-DEC-2007 was vaccinated into the left deltoid with a first dose of dose of GARDASIL vaccine (lot#655327/12870U). Within seconds, the patient turned blue and passed out and was out for about one to one and a half minutes. It was also reported that the patient went to check out 15 minutes later and fell to the floor. 911 was called after the clinical staff rendered emergency care. Unspecified medical attention was sough. At the time of this report, the patient's outcome was unknown. On 28-DEC-2008, the patient recovered. No product quality complaint was involved. Additional information is not expected.
Left arm deltoid slightly red, swollen, tender, pain, warm to touch, swollen deltoid to elbow.
This case was reported in a literature article and described the occurrence of uveitis in a 17-year-old female subject who was vaccinated with hepatitis B vaccine recombinant (Hepatitis B vaccine, manufacturer unspecified). On an unspecified date the subject received 2nd dose of hepatitis B vaccine (unknown). One day after vaccination with Hepatitis B vaccine, the subject experienced uveitis and autoimmune disorder. This case was assessed as medically serious by GSK. This case is one of the 32 reported cases (B0662264A till B0662297A) of uveitis which occurred after hepatitis b vaccine between 1982 and 2009. It appeared that all subject's recovered, although the treatment for uveitis was not reported. The uveitis occurred in average of 3 days after vaccination in patients without other risk factors or disease that could cause uveitis. This could be consistent with immune complex deposition or nonspecific activation from vaccine adjuvants. Although there was a debate that uveitis occurs because of hepatitis B infection there was evidence that immune complex deposition diseases such as glomerulonephritis and cryoglobulinemia occurred during chronic hepatitis B infection. Furthermore it was possible the surface antigen of the vaccine and the hepatitis B antibodies of the immune response after vaccination formed immune complexes, which initiated the ocular response of uveitis.
Headache, NauseaVomiting, lightheadedness, throat numbness, facial tingling Narrative: 12/28 Onset of lightheadedness within 5 minutes of vaccine followed by nausea. After 35 min she felt tingling on her face and felt like her throat was numb. She drank water with no problem. She checked her O2 sat and it remained 91 - 93%. She just had an O2 meter because her Mother-in-law gave it to her. No underlying lung problem. She continues to have mild nausea but other symptoms have resolved. She has been able to eat some food which is making her feel better. She says she is developing tenderness in her temples which feels like she's developing a headache.
This spontaneous report as received from a registered nurse refers to a male patient of unknown age. The nurse reported that on 09-JUN-2012, the patient was vaccinated with, 0.5 ml VARIVAX (Merck) (Lot # not reported) SQ, instead of ZOSTAVAX. No adverse event was reported. There was no co-suspect reported. There were no concomitant medications reported. It was also reported that this was an office error and not a product confusion for any other reason. Additional information has been requested.
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown age and gender. On an unspecified dates in approximately 2014 (also reported as since May 2014), an unspecified number of patients were administered RECOMBIVAX HB (dose, route of administration, lot# and expiration date were not provided) that fell to a temperature of 33F. This excursion was supported. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.
very irritable for several HR p/vax 5DEC96;had ? fever not taken;
I noticed body aches, fatigue and fever of 99.2. The symptoms were generally mild. Today is the 1st day without all of the symptoms. I went to urgent care on December 1st, and was swabbed for strep; COVID-19, and flu. They advised me to do over the counter medications and did not prescribe any medication. The fever has finally gone away. I am still a little stuffy and have a sore throat with sinus drainage. I do have sinus issues developing and I am unsure whether they are related
Erythema - 12 cm and Induration - 4 cm around injection site.  No fever.  Started evening after administration.  Measured 2 days after administration 02/11/2010 Initial and follow up information has been received from a physician concerning a 7 year old male with no known allergies or pertinet medical history, wha on the morning of 05-MAR-2007 was vaccinated SC in the left thigh with second dose of VARIVAX (lot # 654526/1141P). Concomitant vaccineation included a first dose of VAQTA (lot # 656497/1213F) given IM in the left vastus lateralis. THere was no illness at the time of vaccination. Subsequently, that evening, the patient developed a local site reaction 12 x 12 cm erythema and 4 x 4 cm induration around the VARIVAX (lot # 654526/1141P) injection site (also reported to be a fairly large local reaction ). There were no lab test performed. The patietn was treated with KEFLEX. The signs and symptomas resolved "in a few days." THe patient was considered recovered. In follow-up, it was reported the reaction resolved repidly. The patient had no adverse events following prior vaccination. Additional information is not expected.
sweat profusely from his head, chest and arms; Started feeling of nausea; This is a spontaneous report received from a contactable reporter(s) (Pharmacist).  A 22 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 21Oct2021 (Lot number: FF2589, Expiration Date: Dec2021) at the age of 22 years as dose number unknown, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: HYPERHIDROSIS (non-serious) with onset 21Oct2021, outcome "unknown", described as "sweat profusely from his head, chest and arms"; NAUSEA (non-serious) with onset 21Oct2021, outcome "unknown", described as "Started feeling of nausea". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of hyperhidrosis, nausea.  Additional information: While confirming the date of adverse event, Pharmacist added, Immediately, it was immediately right after. The man started to sweat profusely from his head, chest, and arms. We gave the patient orange juice and he started to feel better, orange juice, no medication. Pharmacist also stated, yes, the patient immediately started feeling of nausea and then the sweating it happen like right after he got the shot. He don't know, we asked him if he has suffered from anxiety with vaccine or getting shot, he said no. His heartbeat did not increase so was not a panic attack. When the paramedics came out, they checked his temperature, which was normal, his blood sugar was normal, his heart rate was normal, and his blood pressure was also normal. He has no known drug allergies. He has never had an adverse reaction to any vaccine. He has no underlying conditions and no medications. No other Products and Investigation assessment was reported.  No follow-up attempts are possible. No further information is expected.
After receiving Tdap shot, employee reports sharp pain to left arm, with activity. No swelling noted. Left arm injection site is tender to touch. Pain level is 2/10.
About one week after vaccine, I had right shoulder and  achiness and achiness along my right clavicle.  On 4/4/2021, I noticed a swollen and tender lymph node above my right clavicle.  On 4/8/2021, I measured the node .  It measures about 1 by 1.5 cm.
Admitted 11/20/21 w/ respiratory distress, up to 5L O2 requiring floor admit.
Patient reports left arm swelling , redness and warmth. Patient was given doxycycline at urgent care and told to take zyrtec and tylenol as needed.
Sore throat; congested; 2nd dose - lethargic for 24 hours.; intense muscle and joint pain for about 48 hours from proximal kneels to neck (hurt to move, shoulder flexibility pain free range 0-30 degrees, couldn't lay on right arm).; intense muscle and joint pain for about 48 hours from proximal kneels to neck (hurt to move, shoulder flexibility pain free range 0-30 degrees, couldn't lay on right arm).; first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 18Dec2020/ second dose of BNT162B2 on 06Jan2021; first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 18Dec2020/ second dose of BNT162B2 on 06Jan2021; This is a spontaneous report from a contactable consumer (patient). A 35-year-old female patient received her second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: Ek9231, expiration date 30Apr2021), via an unspecified route of administration on right arm at 08:30 AM on 06Jan2021 at single dose for COVID-19 immunization. Medical history included hypothyroid. Concomitant medication included levothyroxine, vitamin c [ascorbic acid] (VITAMIN C [ASCORBIC ACID]), colecalciferol (VITAMIN D) and multivitamin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received her first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 18Dec2020 at single dose for COVID-19 immunization and experienced minimal pain right deltoid area. For the second dose, the patient experienced lethargic for 24 hours, intense muscle and joint pain for about 48 hours from proximal kneels to neck (hurt to move, shoulder flexibility pain free range 0-30 degrees, couldn't lay on right arm). Took Tylenol to decrease muscle and joint pain, which helped. Day 4 post vaccine on 10Jan2021, slight sore throat, congested, but muscle and joint pain generally resolved. It was only day 4. The outcome of events muscle pain and joint pain was recovered on 10Jan2021, the outcome of reset events was not recovered. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the had not patient been tested for COVID-19.
MOTHER CALLED AND REPORTED CHILD DEVELOPED HIVES FROM HEAD TO TOE 24 HOURS AFTER RECEIVING H1N1 VACCINE. NO OTHER SYMPTOMS WITH HIVES.  CHILD TAKEN TO PRIMARY MEDICAL DOCTOR. CHILD GIVEN BENADRYL. FOLLOW-UP PHONE CALL TO MOTHER REPORTS CHILD IS FINE AND HAD NO OTHER PROBLEMS.
Significant nausea that came on about 24 hours after the injection. No vomiting. Symptoms are significantly improved and subsiding at the time of this report.
Patient was deemed appropriate to be monitored for 15minutes.  During observation time at roughly 1145 she noted burning of her lips which transitioned to numbness.  At this time vitals were taken: HR 96, RR 18, 99% RA, BP 192/88   Burning of the lips resolved.  Face became flushed and described as very warm and burning and that her voice was becoming hoarse.   50mg PO Benadryl was given at 1159.  Throughout she denied any CP, SOB, cough, oral ulceration, tongue swelling, throat swelling  Brief exam: Lungs clear bilaterally without any wheezing, no wheezing heard in the upper airway.  RRR.  Skin of the face flush and warm no diaphoresis.  Lips had no circumoral palor or cyanosis.  Did note some redness and chapped areas at the vermilion boarder.  No swelling of the tongue or below the tongue.  No oral ulcerations, erythema or pharyngeal swelling.  No other rash of the skin.   Individual was taken to the ER for observation at 1205.
This is a spontaneous report received from contactable consumer or other non-HCP. A 31-year-old male patient received the 2nd dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), single dose, for COVID-19 immunisation. No medical history or concomitant medications reported. Vaccination history included the 1st dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine), for COVID-19 immunisation. The patient experienced pain/body aches, chills, fatigue/exhaustion, with outcome of recovered. The events lasted for exactly 24 hours. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected.
Knee pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Knee pain) in a female patient of an unknown age who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.    On 31-Oct-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (Knee pain). At the time of the report, ARTHRALGIA (Knee pain) outcome was unknown.        For mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown), the reporter did not provide any causality assessments.   Concomitant and treatment medications were not reported.  Patient was asking that she can take ibuprofen for several days due to knee pain. Will ibuprofen reduce the effectiveness of the vaccine.   Most recent FOLLOW-UP information incorporated above includes: On 02-Nov-2023: Live follow-up received contains significant information: Patient details, event details, references and narrative were updated.
got tested positive; got tested positive; This is a spontaneous report from a Pfizer Sponsored Program . A contactable consumer reported for himself that a male patient with unknown age received first dose of bnt162b2 (Pfizer-BioNTech COVID-19 mRNA vaccine, Lot Number and Expiration Date unknown) via an unspecified route of administration on an unknown date at single dose for COVID-19 immunisation. The patient's medical history and concomitant medications was not reported. Patient received the first dose of the Pfizer shot and he got tested positive and had symptoms (but the caller did not provide the specific symptoms). He is scheduled to get the second dose on 16Feb2021. Patient wanted to know if he can take the second dose on the scheduled one or he should delay it. The outcome of event was unknown.  Information on the lot/batch number has been requested.
Pt. developed rash on both hands about 3 days after receiving Zostavax vaccine.  Also saw some white lines extending from thumb area.  Rash described as mild.